International Journal of Breast Cancer

International Journal of Breast Cancer is a gold open-access oncology journal published by Wiley, running since 2010 and devoted to clinical, translational and laboratory work across the whole breast cancer pathway, with a 2025 Journal Impact Factor of 1.9.《国际乳腺癌杂志》是由 Wiley 出版的金色开放获取肿瘤学期刊，2010 年创刊，刊载贯穿乳腺癌诊疗全路径的临床，转化与实验室研究，2025 年期刊影响因子为 1.9。

Scope

• The declared remit runs from molecular pathology to population screening, and the editors favour work that changes how a question is framed or how a patient is managed.刊物声明的范围从分子病理延伸到人群筛查，编辑部偏好能改变问题提法或患者处理方式的稿件。

• Tumour biology forms the base, covering receptor signalling, clonal evolution, the immune microenvironment and the transcriptional programmes that separate the intrinsic subtypes.肿瘤生物学构成基础，涉及受体信号，克隆演化，免疫微环境，以及区分内在亚型的转录程序。

• Hereditary risk is handled as mechanism and as clinical service at once, from BRCA1 and BRCA2 testing through variant interpretation to cascade screening of relatives.遗传性风险同时按机制与临床服务处理，从 BRCA1 与 BRCA2 检测，经变异解读，到亲属的级联筛查。

• Pathology papers earn a place when they sharpen diagnosis, grading or biomarker scoring, including the reproducibility of immunohistochemistry from one laboratory to the next.病理学论文若能改进诊断，分级或生物标志物评分即可入列，包括免疫组化在实验室之间的可重复性。

• Imaging coverage spans mammography, digital breast tomosynthesis, ultrasound, contrast-enhanced and diffusion-weighted magnetic resonance, and the reading algorithms now attached to those modalities.影像覆盖乳腺 X 线摄影，数字乳腺断层合成，超声，增强与弥散加权磁共振，以及附着于这些模态的阅片算法。

• Screening attracts sceptical work as well as promotional work, so studies of interval cancers, overdiagnosis and recall rates sit beside reports of detection gains.筛查领域既收肯定性研究，也收怀疑性研究，间期癌，过度诊断与召回率的论文同检出率增益的报告并列。

• Operative topics include breast-conserving technique, oncoplastic reconstruction, sentinel-node biopsy and the retreat from routine axillary dissection in clinically node-negative disease.手术选题包括保乳技术，肿瘤整形重建，前哨淋巴结活检，以及临床淋巴结阴性病例中放弃常规腋窝清扫的当下趋势。

• Radiation oncology contributions deal with hypofractionation, partial-breast irradiation, accelerated schedules and the dose constraints that decide late cardiac and pulmonary toxicity.放射肿瘤学稿件讨论大分割，部分乳腺照射，加速日程，以及决定晚期心脏与肺毒性的剂量约束。

• Systemic therapy is covered across chemotherapy, endocrine treatment, CDK4/6 inhibition, PARP inhibitors, antibody-drug conjugates and checkpoint blockade, with resistance as a standing theme.全身治疗覆盖化疗，内分泌治疗，CDK4/6 抑制，PARP 抑制剂，抗体偶联药物与检查点阻断，耐药是贯穿始终的主题。

• Neoadjuvant and adjuvant strategies are examined for escalation and de-escalation alike, and pathological complete response is used both as an endpoint and as a decision point.新辅助与辅助策略从升阶与降阶两个方向考察，病理完全缓解既作终点也作决策节点。

• Metastatic disease has room for oligometastatic treatment, liquid-biopsy monitoring and the sequencing of therapy lines after resistance appears at a particular organ site.转移性疾病为寡转移治疗，液体活检监测，以及耐药在特定器官部位出现之后的治疗线序留出篇幅。

• Epidemiology, registry analysis and health-services research belong in scope, especially where they expose differences in stage at diagnosis between populations or between health systems.流行病学，登记数据分析与卫生服务研究属于收录范围，尤其在其揭示不同人群或不同卫生体系之间确诊分期差异之处。

• Prevention work covers risk models, chemoprevention, risk-reducing surgery and the counselling that has to accompany a genetic result once it reaches a family.预防研究涵盖风险模型，化学预防，降低风险手术，以及基因结果进入家庭之后必须伴随的咨询。

• Survivorship appears through lymphedema, cardiac late effects, fertility preservation, body image and the psychosocial burden that outlasts active treatment by years.生存者议题经由淋巴水肿，心脏晚期效应，生育力保存，身体意象，以及比积极治疗延续数年的心理社会负担进入刊物。

• Manuscripts must fit one of the accepted article types, chiefly original research and reviews, and describe methods closely enough for another group to repeat the work.稿件须符合已接受的体裁，主要是原创研究与综述，并把方法写到别的课题组能够重复的程度。

History

• Volume one appeared in 2010, issued from Cairo by Hindawi Publishing Corporation, a company that had grown quickly on a born-digital open-access model.首卷于 2010 年问世，由设在开罗的 Hindawi Publishing Corporation 出版，这家公司靠原生数字的开放获取模式迅速成长。

• The launch came late against the disease burden, since breast cancer already had several specialist journals, and a newcomer had to compete on speed and on licence terms.相对于疾病负担，创刊时间偏晚，乳腺癌当时已有数份专门期刊，新刊只能在出版速度与许可条款上竞争。

• Each paper carried a volume year and an article identifier from the outset, a scheme that removed page ranges and issue bundles from the publishing routine.每篇论文从一开始就带卷年与文章编号，这套方案把页码范围与期次合订从出版流程中去掉。

• PubMed took the journal from the 2011 volume, and deposit in PubMed Central followed, which put the content in front of clinicians who rarely open a publisher site.PubMed 自 2011 年卷起收录本刊，随后进入 PubMed Central，内容由此到达很少打开出版商网站的临床医生面前。

• Growth through the 2010s leaned on special issues, many of them guest-edited around a single theme such as triple-negative disease or imaging in dense breasts.2010 年代的扩张依靠专题辑，其中不少由客座编辑围绕三阴性病变或致密型乳腺影像等单一主题组织。

• Output stayed modest by open-access standards and the citation base grew slowly, which kept the title outside the leading quartile of its category for most of that decade.按开放获取的标准衡量，发文量一直不大，引文基础增长缓慢，刊物在那十年的大部分时间里都排在本类目的第一四分位之外。

• In 2021 Wiley, which had been distributing Hindawi titles on its platform, bought the company, and the Cairo operation was folded into a larger publishing group.2021 年，一直在自家平台上发行 Hindawi 刊物的 Wiley 收购了这家公司，开罗的业务并入一个更大的出版集团。

• The imprint changed in 2023, when the National Library of Medicine began recording Philadelphia as the place of publication and Wiley as the publisher.2023 年出版商标记发生变化，美国国家医学图书馆开始把出版地记为费城，把出版方记为 Wiley。

• Hosting moved with the imprint, from the hindawi.com journal pages to Wiley Online Library, and the old addresses now redirect instead of serving full text.托管平台随标记一同迁移，从 hindawi.com 的刊物页转到 Wiley Online Library，旧地址如今只做跳转，不再提供全文。

• A research-integrity review then ran across the acquired list, and several thousand papers were retracted group-wide after investigations into paper-mill activity.随后集团对收购来的刊物开展科研诚信审查，在论文工厂调查之后，整个组合撤销了数千篇论文。

• Wiley retired the Hindawi brand in 2024 and kept the titles that survived the review inside its own programme, which is where this journal now sits.Wiley 于 2024 年停用 Hindawi 品牌，通过审查的刊物并入自家出版计划，本刊目前就在其中。

• The disruption shows in the numbers, with the 2025 Journal Citation Reports counting 23 articles for the year, 558 citations in total and a cited half-life of 9.2 years.这段动荡体现在数字上，2025 年期刊引证报告录得当年 23 篇论文，总被引 558 次，引用半衰期 9.2 年。

• The impact factor went from 1.6 in 2023 to 3.0 in 2024 and back to 1.9 in 2025, a swing driven by a small denominator rather than by reputation.影响因子从 2023 年的 1.6 升到 2024 年的 3.0，2025 年又回到 1.9，这一起伏源于分母偏小，与学术声望关系不大。

• In the 2025 Journal Citation Reports the title holds a fourth-quartile place in Oncology, ranked 259 of 333 within the Emerging Sources Citation Index.在 2025 年期刊引证报告中，该刊在肿瘤学类目位列第四四分位，在新兴来源引文索引的 333 份刊物中排第 259 位。

• Every article has been free to read on the day it appears since 2010, and the gold open-access share recorded for 2025 is a full 100 per cent.自 2010 年起，每篇论文在刊出当日即可免费阅读，2025 年记录的金色开放获取比例为 100%。

Editors

• Decisions rest with the academic editor assigned to a manuscript, and that person's name is printed on the article alongside the submission and acceptance dates.裁定权属于被指派处理某篇稿件的学术编辑，论文刊出后其姓名与投稿，录用日期一并印在文章上。

• The arrangement carried over from the Hindawi years, when a large board of academic editors replaced the small central team common at subscription journals.这套安排沿用自 Hindawi 时期，当时以一批学术编辑取代订阅制期刊常见的小型中心团队。

• Board coverage follows the clinical pathway, so surgical, medical and radiation oncology sit beside pathology, radiology and nursing expertise on the same panel.编委构成沿临床路径展开，外科肿瘤学，内科肿瘤学与放射肿瘤学同病理学，放射学与护理学专长同处一个名单。

• Review is single anonymous, as the journal's own record states, so referees know who wrote the paper while authors never learn who assessed it.评审采用单匿名方式，刊物自己的记录如此写明，审稿人知道论文作者，作者则始终不知评审者是谁。

• Submissions pass similarity and image screening before an academic editor sees them, a step the publisher tightened across its portfolio after 2023.稿件在学术编辑看到之前先经文本相似度与图像筛查，出版商在 2023 年之后于整个组合收紧了这一步。

• Authors submit through the publisher's own system, and a file moves to review only after the format and the ethics declarations are complete.作者通过出版商自有系统投稿，格式与伦理声明齐全之后，稿件才进入评审。

• Ethical approval, trial registration and data-availability statements are checked at that stage, and a missing approval letter stops the file instead of delaying it.伦理批件，试验注册与数据可得性声明在这一阶段核查，缺少批准文件会使稿件停下，而不会延后处理。

• Reports that need statistical reworking go back to the authors with a request for the analysis code, a habit that grew out of the retraction episode.需要重做统计的报告会退回作者并索取分析代码，这一习惯源自那场撤稿风波。

• Revised manuscripts return to the same academic editor, who weighs the response letter against the text instead of restarting the assignment from scratch.修改稿回到同一位学术编辑手中，其把答复信与正文对照权衡，不会从头重新指派。

• Guest editors assemble special issues, and the papers inside them take the ordinary review route rather than a shortened one reserved for invited names.客座编辑组织专题辑，其中的论文走常规评审流程，不走为受邀作者保留的短通道。

• Review articles are accepted from authors who were never invited, though the board commissions some of them to keep fast-moving topics current.综述也接受未经邀约的投稿，编委会另会约请一部分，以跟上快速演进的主题。

• Corrections, expressions of concern and retractions follow the publisher's research-integrity procedure, which is aligned with the guidance issued by COPE.更正，关注声明与撤稿按出版商的科研诚信程序处理，该程序与出版伦理委员会发布的指南一致。

• Authors in countries covered by the publisher's waiver scheme pay nothing, and everyone else meets a flat article processing fee instead of page charges.属于出版商减免计划覆盖国家的作者不付费，其余作者按篇缴纳固定的文章处理费，不再另设版面费。